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Background/aim: This study aimed to describe the prognostic importance of epidermal growth factor (EGFR), phosphatase and tensin
homolog (PTEN), human EGF receptor-2 (HER-2), and insulin-like growth factor 1 receptor (IGF-1R) in gastric cancer patients treated
with postoperative chemoradiation therapy.
Materials and methods: Sixty-nine patients treated with adjuvant chemoradiation therapy were retrospectively evaluated. Tumor
samples were stained immunohistochemically.
Results: All patients were treated with 3D conformal radiation therapy with concomitant and adjuvant chemotherapy. Perineural
invasion (PNI) (P = 0.042), prechemoradiation therapy albumin levels below 3.5 mg/dL (P = 0.011), and EGFR positivity (P = 0.008) had
negative effects on overall survival (OS). The median OS was 26 months for patients with PNI (+), 34.9 months for those with PNI (–),
19.5 months for those with albumin levels below 3.5 mg/dL, and 33.2 months for those with albumin levels above 3.5 mg/dL. IGF-1R (+)
(P = 0.035) and history of cigarette smoking (P = 0.033) were observed to have a statistically significantly negative effect on disease-free
survival (DFS). The median DFS was 29.2 months for IGF-1R (+) patients, 37.9 months for those with IGF-1R (-), and 26.3 and 40.59
months for smokers and nonsmokers, respectively.
Conclusion: IGF-1R and EGFR may be used for patient selection in future prospective studies that evaluate the prognostic importance
of these receptors.
Key words: Gastric cancer, PTEN, EGFR, HER-2, IGF-1R, radiotherapy

1. Introduction
Gastric cancer is the second leading cause of cancerrelated mortality worldwide with the highest mortality
rates being reported in East Asia [1]. As it is diagnosed
at an advanced stage of the disease, the 5-year survival
rate of patients with gastric cancer is lower than 20%
[2]. The main treatment for gastric cancer is surgery [1].
Although surgery is the only possible curative treatment,
the distant and regional recurrence rates of postresection
curative treatment are still high. Consequently, adjuvant
therapies such as radiation therapy (RT), chemotherapy
(CT), or chemoradiation therapy (CRT) have been studied
in patients with gastric cancer after surgical resection
[3]. Neoadjuvant or adjuvant therapy is recommended in
patients at stage 2 and those at advanced stages or in nodepositive patients, which might improve the treatment
outcomes. The Intergroup 0116 study, a randomized
phase 3 trial, compared observation versus adjuvant
chemoradiation therapy. This study showed the advantages

of combined adjuvant therapy on overall survival (OS) [4].
Prognosis for patients with locally advanced stage disease
is poor despite multimodal therapy. Consequently, new
strategies must be developed to improve the outcomes.
The most significant prognostic indicator for gastric
cancer is tumor stage. Lymph node involvement and the
number and localization of lymph nodes are also important
risk factors [5]. Particular attention should be given to
the biomarkers that might assist in defining subgroups
of the individual therapies [6]. These novel prognostic
factors include phosphatase and tensin homolog (PTEN),
epidermal growth factor (EGFR), human EGF receptor-2
(HER-2), and insulin-like growth factor 1 receptor (IGF1R). EGFR is localized on the external cell surface and
is a member of the tyrosine kinase (TK) receptor family.
EGFR overexpression is observed in various human
malignancies including lung, breast, colon, and gastric
cancers [7]. EGFR has been shown to be a dependent
prognostic factor in numerous types of cancers. The
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clinical role of EGFR in gastric cancer is not clear. HER-2
is a transmembrane TK receptor [8,9]. Intestinal-type and
well-differentiated gastric cancers have a higher rate of
HER-2 positivity than poorly differentiated and diffusedtype gastric cancers [7]. The overexpression of HER-2 and
EGFR is associated with poor prognosis and has been
reported in approximately 30%–50% of gastric cancers
[10,11]. PTEN is a tumor-suppressor gene localized
on chromosome 10 [12]. Studies have reported that
inactivation of the PTEN gene is closely associated with
the progression and incidence of gastric cancer [13]. The
PTEN protein affects apoptosis, migration, metabolism,
transcription, and translation and also inhabits cellular
invasion and metastasis [14]. Due to genetic modification,
PTEN gene inactivation might be observed in endometrial
carcinoma, glioblastoma multiforme, prostate, skin, and
breast cancers [3]. IGF-1R is a membrane cell receptor
that is frequently overexpressed in human cancers [11].
IGF-1R has a role in cellular proliferation, malignant
transformation, differentiation, and prevention of
apoptosis [15]. There is a relationship between IGF-1R
and survival in breast cancer and solid tumors, but IGF1R expression in gastric cancer is poorly understood.
IGF-1R expression is a predictor for poor results [11]. The
overexpression of IGF-1 was distinct in large tumors with
high mitotic activity, and it was correlated with high risk of
malignancy. The overexpression of IGF-1R was correlated
with the overexpression of IGF, high mitotic activity, and
high risk of malignancy [16].
The present study was designed to define the prognostic
importance of HER-2, IGF-1R, PTEN, and EGFR in gastric
cancer patients treated with postoperative chemoradiation
therapy.
2. Materials and methods
The hospital records of 69 patients with nonmetastatic
gastric cancer were retrospectively evaluated between
January 2010 and October 2013. The study was approved
by the Ethics Committee of Necmettin Erbakan
University. Paraffin-embedded tumor samples were
immunohistochemically stained for PTEN, EGFR, HER-2,
and IGF-1R. All patients were treated with 3D conformal
radiation therapy with concomitant and adjuvant
chemotherapy. Formalin-fixed paraffin-embedded (FFPE)
tumor samples were immunohistochemically stained for
PTEN, EGFR, HER-2, and IGF-1R. Sections of tumor
blocks of 4 µm were stained with hematoxylin and eosin,
and the samples were evaluated by a pathologist. All
reagents and equipment for immunohistochemistry (IHC)
were manufactured by Ventana Medical Systems (Tucson,
AZ, USA). FFPE sections were stained automatically with
Ventana Benchmark XD by using primary antibodies
directed against EGFR, PTEN, HER-2, and IGF-1R.
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A scoring system based on the variability of staining
intensity was used. Brown membranous staining was
considered positive for HER-2. The results were evaluated
as follows: 0, no staining or membranous reactivity in <10%
of cells; (+), faintly to barely perceptible membranous
reactivity in >10% of cells; (++), basolateral membranous
staining of weak to moderate intensity in >10% of cells;
and (+++), basolateral membranous staining of strong
intensity in >10% of cells [9]. EGFR and IGF-1R tumor
cell membrane immunostaining was scored as 0, 1+ ,
2+, or 3+. The results were evaluated as follows: 0, no
membranous reactivity within the tumor; 1+, 2+, or 3+,
depending on the intensity above the background level
[1,15]. For EGFR, IGF-1R, and HER-2, an IHC score of 3+
was defined as positive. The intensity of staining for PTEN
was scored using a 0 to 3 grading system: 0, negative; 1,
weak; 2, moderate; and 3, strong. The level of PTEN
staining was evaluated by calculating the immunoreactive
score (IRS) from the staining intensity and the percentage
of PTEN-positive cells [17]. IRS = 0 and IRS = 2–3 were
considered as negative and positive, respectively. The total
PTEN expression was calculated as cytoplasmic PTEN
expression + nuclear PTEN expression.
2.1. Statistical analysis
Statistical analysis was performed using SPSS 16.0 (SPSS
Inc., Chicago, IL, USA). Primary and secondary outcomes
were OS and disease-free survival (DFS). The time from
diagnosis to the date of the patient’s death or last followup was defined as OS. The time from diagnosis to the date
of the documented progression, distant metastases, or
recurrence was defined as DFS. Survival was calculated
with the Kaplan–Meier method and a log-rank test.
Fisher’s exact test was used to analyze HER-2, IGF-1R,
PTEN, and EGFR (positive or negative) and univariate
correlations between clinicopathological variations.
Multivariate analysis of the data was performed using the
Cox proportional hazards model. P < 0.05 was accepted as
statistically significant.
3. Results
3.1. Patient and tumor characteristics
Of the patients, 72.5% were male and 27.5% were female.
The median age was 59 years (range: 34–80 years), and
65.2% were smokers. Karnofsky performance scores
of all patients were above 70. The median follow-up
period was 15.9 months (range: 3.2–44.68 months).
Tumors were localized in the cardia, antrum, corpus, and
fundus of 27.5%, 31.9%, 39.1%, and 1.4% of the patients,
respectively. The median period between surgery and
RT was 68 days (range: 34–284 days). D2 dissection
was implemented in 82% of patients. All patients were
treated with 3D conformal radiation therapy with
concomitant and adjuvant chemotherapy. In 31.9% (n

BENLİ YAVUZ et al. / Turk J Med Sci
= 22) of the patients, inadequate lymph node dissection
was performed, and 7 of these patients were stage 1. The
radiation dose for postoperative adjuvant therapy was
45–50.4 Gy. Adjuvant chemotherapy was administered for
5.8% (n = 4) of patients with TCF, 63.7% (n = 44) with
FUFA, and 30.4% (n = 21) with CF. The median serum
albumin level was 3.8 mg/dL prior to treatment (range:
2.4–3.8 mg/dL). Histopathological examination revealed
adenocarcinoma in 75.7% (n = 53) of patients and signetring cell adenocarcinoma in 24.3% (n = 16) of patients
(Table 1). There was no statistically significant difference
in EGFR and PNI in stage 1, 2, and 3 (Table 2). Distant
metastasis was observed in 12 patients and local recurrence
was not defined. HER-2, EGFR, IGF-1R, and PTEN were
positive in 9 (13%), 10 (14.5%), 24 (34.8%), and 45 (65.2%)
patients, respectively (Figure 1).
Table 1. Patient and tumor characteristics.
n (%)
Sex
Male
Female

50 (72.5%)
19 (27.5%)

Cigarette smoking

45 (65.2%)

Primary location of tumor
Cardia
Antrum
Corpus
Fundus

19 (27.5%)
22 (31.9%)
27 (39.1%)
1 (1.4%)

Type of gastrectomy
Total
Subtotal

30 (43.5%)
39 (56.5%)

Histopathological type
Adenocarcinoma
Signet ring cell adenocarcinoma

53 (75.7%)
16 (24.3%)

Lymphovascular invasion

32 (46.4%)

Perineural invasion

43 (62.3%)

Stage
Stage 1
Stage 2
Stage 3

7 (10.1%)
12 (17.4%)
50 (72.5%)
Median (range)

Age, years

59 (34–80)

Follow-up period, months

15.9 (3.2–44.68)

Period between surgery and RT, days

68 (34–284)

Pretreatment albumin, g/dL

3.8 (2.4–3.8)

Tumor size, cm

1–16

Number of resected lymph nodes

20 (4–52)

Number of involved lymph nodes

2 (0–34)

Table 2. EGFR and PNI distribution according to stages.
Stage 1

Stage 2

Stage 3

P-value

Negative

3 (11.5%)

3 (11.5%)

20 (76.9%)

0.602

Positive

4 (9.3%)

9 (20.9%)

30 (69.8%)

Negative

6 (10.2%)

11 (18.6%)

42 (71.2%)

Positive

1 (10%)

1 (10%)

8 (80%)

PNI

EGFR
0.795

3.2. Survival analysis
The median OS was 41 months. The overall survival rates
at 1, 2, and 3 years were 88%, 56%, and 49%, respectively.
The 1- , 2-, and 3-year DFS rates were 94%, 78%, and 61%,
respectively (Figure 2).
Perineural invasion (PNI) (log-rank; P = 0.042),
prechemoradiation therapy albumin level below 3.5 mg/
dL, and EGFR positivity were found to have negative
effects on OS. The median OS was 26 months for patients
with PNI (+), 34.9 months for those with PNI (–), 19.5
months for those with albumin levels of <3.5 mg/dL, and
33.2 months for those with albumin levels of >3.5 mg/dL.
OS was 16.2 and 32.1 months in EGFR (+) and EGFR (-)
patients, respectively (P = 0.008) (Figure 3).
In univariate analyses, PNI (+) (P = 0.038), albumin
level <3.5 mg/dL (P = 0.035), existence of lymph node
involvement (P = 0.035), and EGFR (+) (P = 0.003) had
negative effects on prognosis. However, in multivariate
analyses, only IGF-1R (+) (P = 0.033) and lymph node
involvement (P = 0.038) had poor prognostic effects
on OS (Table 3a). IGF-1R (+) (log-rank; P = 0.035) and
history of smoking (log-rank; P = 0.033) were observed
to have a statistically significantly negative effect on DFS.
The median DFS was 29.2 months for IGF-1R (+) patients,
37.9 months for those with IGF-1R (-), and 26.3 and 40.59
months for smokers and nonsmokers, respectively. In
univariate analyses, IGF-1R positivity was found to be a
poor prognostic factor for DFS (P = 0.024). In multivariate
analyses, IGF-1R positivity (P = 0.039) and EGFR (+) (P
= 0.038) had positive prognostic effects on DFS (Figure 4)
(Table 3b).
4. Discussion
In our study, 24 of 69 cases (34.8%) of gastric cancer were
positive for IGF-1R expression. We demonstrated that
IGF-1R expression was correlated with prognosis and OS
in gastric cancer. IGF-1R positivity had a prognostic effect
on DFS in both univariate and multivariate analysis. The
positive EGFR expression rate was 14.5% in gastric cancer
tissue. EGFR positivity had a negative impact on OS. The
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A. a) HER2, 1 + ,100×

B.a)EGFR, 1 + ,100×

C.a)PTEN, 1 + ,100×

b)HER2, 2 +,100×

c)HER2, 3 + ,100×

b)EGFR, 2 + 100×

b)PTEN, 2 + ,100×

D. a)IGF - 1R, 1 + ,100× b)IGF - 1R, 2 + ,100×

c)EGFR, 3 + ,100×

c)PTEN, 3 + ,100×

c)IGF - 1R, 3 + ,100×

Figure 1. Typical examples of positive immunohistochemical staining for HER-2 (A), EGFR (B), PTEN (C), and IGF-1R (D).
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Figure 2. Kaplan-Meier curves for overall survival and disease-free survival.

Figure 3. Relationships between overall survival and PNI, EGFR expression, and preoperative albumin.

median OS rates were 16.2 and 32.1 months in EGFR
(+) and EGFR (-) patients, respectively (P = 0.008). In
multivariate analysis, EGFR positivity had a negative effect
on DFS (P = 0.038). In our study, HER-2 and PTEN were
not prognostic factors in gastric cancer patients.
The correlation between IGF-1R expression and
outcome was shown for breast and other solid tumors.
However, the role of IGF-1R expression is not clearly
defined in gastric cancers. Matsubara et al. showed that
IGF-1R expression was a significant independent predictor
of poor outcomes. However, EGFR and HER-2 were not
related to OS [11,18].
EGFR is the most important member of the growth
factor receptor family. EGFR expression was found to be
related to survival in gastric cancer patients [6,11,18,19].
Atmaca et al. reported similar median OS in patients with
positive EGFR compared to those with negative tumors

[6]. Zhang et al. detected a positive correlation between
high EGFR expression and cetuximab response in gastric
cancer [20]. Cetuximab, lapatinib, and panitumumab are
anti-EGFR inhibitors. The EXPAND study, a randomized
phase 3 trial, compared capecitabine plus cisplatin alone
versus cisplatin + capecitabine + cetuximab therapy. The
median progression-free survival (PFS) and OS were 5.6
and 10.7 months, respectively, in the capecitabine plus
cisplatin group compared to 4.4 and 9.4 months in patients
receiving capecitabine plus cisplatin and cetuximab (P
= 0.315 and P = 0.954). The addition of cetuximab to
capecitabine + cisplatin provided no additional benefit to
the first-line treatment of advanced gastric cancer [21].
The REAL-3 study, a randomized phase 3 trial,
compared panitumumab plus chemotherapy with
chemotherapy in 553 patients with advanced esophageal
and gastric cancer. However, the survival rate in the
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Table 3. Cox regression multivariate analysis of prognostic
factors for OS (a) and DFS (b) in all patients.
a)
P-value

95% CI

HER-2

0.238

0.313–1.651

IGF-1R

0.033

1.095–8.355

EGFR

0.477

0.335–10.35

PTEN

0.943

0.451–2.355

Lymph node

0.038

0.576–2.902

Smoking

0.282

0.314–1.401

P -value

95% Cl

HER-2

0.959

0.000–2.448

IGF-1R

0.039

0.001–0.909

EGFR

0.038

0.006–2.944

PTEN

0.789

0.110–9.512

Lymph node

0.769

0.056–49.05

Smoking

0.694

0.000–5.688

b)

combination arm was lower than that in the chemotherapyalone arm (PFS, 6.0 months vs. 7.4 months, P = 0.068; OS,
8.8 months vs. 11.3 months, P = 0.013) [22].
The overexpression of HER-2 occurs in 10%–30%
of gastric cancers [23]. While HER-2 overexpression is
associated with aggressive tumor biology in breast cancer
[24], its prognostic importance in gastric cancer is less
clear. It was suggested in early studies of gastric cancer that
HER-2 had a negative effect on prognosis [9]. However,
later studies did not find any prognostic effect of HER-2
[1]. Trastuzumab (a monoclonal antibody targeted against
HER-2) causes antibody-dependent cellular cytotoxicity
and inhibits HER-2 receptor signalization [9]. Trastuzumab
is a standard therapy for early-stage and metastatic HER2-positive breast cancers [9]. In the ToGA study, the
OS for HER-2-positive gastric cancers was significantly
improved when trastuzumab was used in combination
with chemotherapy rather than chemotherapy alone. The
overall HER-2 positivity rate was 22.1%, and the median
OS was significantly improved in the trastuzumab group
compared to the chemotherapy control group (13.8 vs. 11.1
months, P = 0.0046) [10]. Trastuzumab plus chemotherapy
was indicated as a novel standard in HER-2-positive gastric
and gastroesophageal junction tumors in the ToGA study.
Masorini et al. showed positivity of EGFR and HER-2 in 75
(9%) and 113 (13.6%) patients, respectively. The overall and
relapse-free survival rates were significantly lower in EGFRpositive patients compared to EGFR-negative patients,
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regardless of HER-2 status. EGFR positivity was associated
with poor outcomes in multivariate analysis [1].
PTEN gene mutation is rarely seen in gastric cancer.
However, loss of heterozygosity (LOH) is rather common
[13]. The LOH rate is significantly higher in advanced
gastric cancer than early-stage gastric cancer (63% and
18%, respectively) and is also significantly higher in poorly
differentiated tumors than well-differentiated gastric
tumors (69% and 29%, respectively) [13]. Zhu et al. stated
in their study that the loss of cytoplasmic PTEN expression
in gastric carcinoma was more common in comparison to
the adjacent nonneoplastic tissues. The loss of cytoplasmic
PTEN was correlated with histological stage. Total loss of
PTEN expression or nuclear loss of PTEN was correlated
with tumor grade. PTEN expression was not significantly
related to the 3-year survival and OS rates [25]. Li et al.
showed that the loss of cytoplasmic PTEN expression was
associated with distant metastasis and advanced clinical
stage in gastric cancer patients [14].
Cigarette smoking and alcohol consumption are
considered potential risk factors for gastric cancer. The
mechanism of how tobacco smoking increases the risk of
gastric cancer is not well understood. The risk of gastric
cancer development is 1.45 times higher in smokers than in
nonsmokers [26]. Han et al. found an association between
cigarette smoking after surgery and poor survival and cancer
recurrence. However, they did not indicate a relationship
between alcohol consumption and survival [27]. In certain
studies, alcohol consumption was found to be significantly
associated with poor outcomes in gastric cancer patients
[28]. Cigarette smoking was an independent risk factor
for DFS, but alcohol consumption was not associated with
survival in our study.
PNI is a poor prognostic factor in certain cancers, such
as head/neck and prostate cancers [29]. It is also correlated
with an aggressive tumor genotype [17]. The prognostic
significance of PNI in gastric cancer has been investigated
in several studies. Duroker et al. stated that PNI did not
add any additional information to classic prognostic factors
[30]. Bilici et al. showed that PNI (–) patients had longer
survival than PNI (+) patients, and PNI was found to be a
prognostic factor for the curative treatment of patients with
gastric cancer [31]. In the study of Deng et al., PNI positivity
was shown to be an independent prognostic factor affecting
OS and DFS of patients with gastric cancer who underwent
curative resection [17]. In our study, there was a significant
difference between PNI (+) and PNI (-) patients in terms
of OS. The median OS was 26.07 and 34.9 months in PNI
(+) and PNI (-) patients, respectively (P = 0.042, log-rank).
The statistical power of our study is weak because
distant metastasis developed in only 12 patients. The power
of HER-2 as a prognostic factor was also weak, as HER-2
positivity was only seen in nine of 69 patients.
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Figure 4. Relationships between disease-free survival and IGF-1R (a) and smoking (b).

In conclusion, this study suggests that IGF-1R, EGFR,
and cigarette smoking can be used as additional prognostic
factors to the previously known prognostic factors in gastric
cancer patients treated with chemoradiation therapy. IGF1R and EGFR may be used for patient selection in future
prospective studies that evaluate the prognostic importance
of these receptors.
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